Utility of Biomarkers in Cardiac Amyloidosis.

Amyloidosis Biomarkers Cardiomyopathies Heart Failure Humans
amyloidosis biomarkers light chains transthyretin

Journal

JACC. Heart failure
ISSN: 2213-1787
Titre abrégé: JACC Heart Fail
Pays: United States
ID NLM: 101598241

Informations de publication

Date de publication:
09 2020
Historique:
received: 18 11 2019
revised: 20 02 2020
accepted: 05 03 2020
pubmed: 13 7 2020
medline: 31 8 2021
entrez: 13 7 2020
Statut: ppublish

Résumé

Cardiac amyloidosis is a growing field, with advancements in diagnosis and management. Cardiac biomarkers are used to predict survival and to develop severity staging systems. Cardiac biomarkers are also used in clinical practice to stratify patients for treatment and to evaluate response to therapies. The current review summarizes the major clinical utility of current biomarkers in patients with cardiac amyloidosis and provides insights about future areas of investigation.

Identifiants

DOI: 10.1016/j.jchf.2020.03.007 PMID: 32653441
pubmed: 32653441
pii: S2213-1779(20)30203-1
doi: 10.1016/j.jchf.2020.03.007
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

701-711

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Published by Elsevier Inc.

Auteurs

Arianna Pregenzer-Wenzler (A)

Cardiac Amyloidosis Program, University of Utah School of Medicine, Salt Lake City, Utah.

Jo Abraham (J)

Cardiac Amyloidosis Program, University of Utah School of Medicine, Salt Lake City, Utah.

Kelsey Barrell (K)

Cardiac Amyloidosis Program, University of Utah School of Medicine, Salt Lake City, Utah.

Tibor Kovacsovics (T)

Huntsman Cancer Institute, Salt Lake City, Utah.

Jose Nativi-Nicolau (J)

Cardiac Amyloidosis Program, University of Utah School of Medicine, Salt Lake City, Utah. Electronic address: jose.nativi@hsc.utah.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies métaboliques et nutritionnelles › Maladies métaboliques › Troubles de l'homéostasie des protéines › Amyloïdose › Utility of Biomarkers in Cardiac Amyloidosis.
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Utility of Biomarkers in Cardiac Amyloidosis.
questionsmedicales.fr › Maladies cardiovasculaires › Cardiopathies › Cardiomyopathies › Utility of Biomarkers in Cardiac Amyloidosis.
questionsmedicales.fr › Maladies cardiovasculaires › Cardiopathies › Défaillance cardiaque › Utility of Biomarkers in Cardiac Amyloidosis.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Utility of Biomarkers in Cardiac Amyloidosis.